TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Study Evaluating the Effects of a Structured Lifestyle Intervention on Daily Physical Activity Level of COPD Patients in the First, Second and Third Echelon.
Brief Summary: Chronic Obstructive Pulmonary Disease (COPD) is increasing in the Netherlands. COPD is characterized by a deterioration of lung function, a lowering physical activity level and a low state of quality of life.

The aim of this randomized controlled study is to investigate the effects of a structured lifestyle program compared with usual care (in the first, second and third echelon) on the physical activity level of COPD patients.

150 COPD patients (GOLD I-IV) will be included, aged between 40 and 80 years. In each echelon 25 patients will participate in a structured lifestyle program and 25 patients will be treated with usual care.

In the structured lifestyle program, patients will be stimulated individually to enhance a physically active lifestyle. The primary outcome parameter is daily physical activity (steps/ day) assessed with a pedometer.

According to the study protocol patients in the experimental group and the control group participate in four measurement sessions distributed over 15 months. In each assessment a physical fitness test, lung function and questionnaires are taken. Patients of the experimental group participate in five individual counseling sessions and one telephonic counseling.


Options:
A: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Other: Ususal care | Arm Label: Intervention; Type: ACTIVE_COMPARATOR; Interventions: Other: RT management | Intervention Type: OTHER; Name: RT management; Assigned to Arm(s): Intervention | Intervention Type: OTHER; Name: Ususal care; Assigned to Arm(s): Control
B: Arm Label: comprehensive care programme; Type: ACTIVE_COMPARATOR; Interventions: Other: Comprehensive care programme | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Comprehensive care programme; Assigned to Arm(s): comprehensive care programme
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Coach, using a stepcounter with exercise counseling | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Coach, using a stepcounter with exercise counseling; Assigned to Arm(s): 1
D: Arm Label: usual care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: care at initiative of the patient (usual GP care) | Arm Label: monitoring controls; Type: EXPERIMENTAL; Interventions: Behavioral: regular practice nurse review (monitoring controls) | Arm Label: self-management; Type: EXPERIMENTAL; Interventions: Behavioral: an integrated self-management education program | Intervention Type: BEHAVIORAL; Name: an integrated self-management education program; Assigned to Arm(s): self-management | Intervention Type: BEHAVIORAL; Name: regular practice nurse review (monitoring controls); Assigned to Arm(s): monitoring controls | Intervention Type: BEHAVIORAL; Name: care at initiative of the patient (usual GP care); Assigned to Arm(s): usual care

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The purpose of this study is to compare the efficacy and safety of tacrolimus vs intravenous cyclophosphamide pulses treatment for the induction therapy of LN(III,IV,V).

To compare the efficacy and safety of tacrolimus vs Azathioprine for the maintenance therapy of LN(III,IV,V).


Options:
A: Arm Label: Tacrolimus; Type: ACTIVE_COMPARATOR; Interventions: Drug: tacrolimus | Arm Label: mycophenolate mofetil; Type: ACTIVE_COMPARATOR; Interventions: Drug: mycophenolate mofetil | Intervention Type: DRUG; Name: tacrolimus; Assigned to Arm(s): Tacrolimus | Intervention Type: DRUG; Name: mycophenolate mofetil; Assigned to Arm(s): mycophenolate mofetil
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: tacrolimus (FK506) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: cyclophosphamide or azathioprine | Intervention Type: DRUG; Name: tacrolimus (FK506); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: cyclophosphamide or azathioprine; Assigned to Arm(s): 2
C: Arm Label: FK506+MMF; Type: ACTIVE_COMPARATOR; Interventions: Drug: Multitherapy | Intervention Type: DRUG; Name: Multitherapy; Assigned to Arm(s): FK506+MMF
D: Intervention Type: DRUG; Name: Abetimus sodium (LJP 394); Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Single-Blind, Randomized Study to Compare DR-2011 to a Progesterone Gel for Luteal Phase Supplementation for In Vitro Fertilization
Brief Summary: This is a multi-center study to evaluate the effects of DR-2011 compared to a progesterone gel in women undergoing in vitro fertilization with fresh eggs. The overall study duration will be approximately 12 months and will involve ovarian suppression/stimulation protocols as well as egg retrieval.


Options:
A: Arm Label: Progesterone SC; Type: EXPERIMENTAL; Interventions: Drug: Progesterone | Arm Label: Progesterone Vaginal gel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Progesterone | Intervention Type: DRUG; Name: Progesterone; Assigned to Arm(s): Progesterone SC | Intervention Type: DRUG; Name: Progesterone; Assigned to Arm(s): Progesterone Vaginal gel
B: Arm Label: Oral dydrogesterone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oral dydrogesterone | Arm Label: Crinone 8% vaginal gel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Crinone 8% gel | Intervention Type: DRUG; Name: Oral dydrogesterone; Assigned to Arm(s): Oral dydrogesterone | Intervention Type: DRUG; Name: Crinone 8% gel; Assigned to Arm(s): Crinone 8% vaginal gel
C: Arm Label: Progesterone 5 Weeks; Type: ACTIVE_COMPARATOR; Interventions: Other: Cease progsterone at 5 | Arm Label: Control Group : P4 8 weeks; Type: OTHER; Interventions: Other: control group: progesterone 8 | Intervention Type: OTHER; Name: Cease progsterone at 5; Assigned to Arm(s): Progesterone 5 Weeks | Intervention Type: OTHER; Name: control group: progesterone 8; Assigned to Arm(s): Control Group : P4 8 weeks
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: DR-2011 | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Crinone 8% | Intervention Type: DRUG; Name: DR-2011; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Crinone 8%; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Clinical Effect and Tolerability of Atorvastatin Versus Placebo in Patients With Pulmonary Hypertension: Double-blinded, Randomised, Prospective Phase II Study for 6 Months With Adjusted Doses of Atorvastatin
Brief Summary: Clinical effect and tolerability of atorvastatin versus placebo in patients with Pulmonary Hypertension: double-blinded, randomised, prospective phase II study for 6 months with adjusted doses of Atorvastatin


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Atorvastatin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
B: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Aspirin | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Atorvastatin | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: Aspirin + Atorvastatin | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Aspirin + Atorvastatin; Assigned to Arm(s): 4
C: Arm Label: atorvastatin 10 mg, 80 mg; Type: EXPERIMENTAL; Interventions: Drug: statin | Intervention Type: DRUG; Name: statin; Assigned to Arm(s): atorvastatin 10 mg, 80 mg
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atorvastatin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective Randomized Controlled Trial to Evaluate Fast Track Recovery in Elective Open Infrarenal Aortic Aneurysm Repair
Brief Summary: Fast track programs have been introduced in many surgical fields to minimize postoperative morbidity and mortality. Morbidity after elective open infrarenal aneurysm repair is as high as 30%, mortality ranges up to 10%. In terms of open infrarenal aneurysm repair no randomized controlled trials exist to introduce and evaluate such patient care programs.


Options:
A: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Traditional management | Arm Label: B; Type: EXPERIMENTAL; Interventions: Procedure: Fast track patient management | Intervention Type: PROCEDURE; Name: Fast track patient management; Assigned to Arm(s): B | Intervention Type: PROCEDURE; Name: Traditional management; Assigned to Arm(s): A
B: Arm Label: 1; Type: OTHER; Interventions: Procedure: Standard Care | Arm Label: 2; Type: OTHER; Interventions: Procedure: Fast Track care | Intervention Type: PROCEDURE; Name: Standard Care; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Fast Track care; Assigned to Arm(s): 2
C: Arm Label: Test; Type: EXPERIMENTAL; Interventions: Dietary Supplement: PreOP Booster (oral nutritional supplement, food for special medical purposes) | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: PreOP Booster (oral nutritional supplement, food for special medical purposes) | Intervention Type: DIETARY_SUPPLEMENT; Name: PreOP Booster (oral nutritional supplement, food for special medical purposes); Assigned to Arm(s): Control, Test
D: Arm Label: OCH; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Preoperative Oral Carbohydrate | Arm Label: FSD; Type: NO_INTERVENTION; Interventions: Dietary Supplement: Preoperative Oral Carbohydrate | Intervention Type: DIETARY_SUPPLEMENT; Name: Preoperative Oral Carbohydrate; Assigned to Arm(s): OCH | Intervention Type: DIETARY_SUPPLEMENT; Name: Preoperative Oral Carbohydrate; Assigned to Arm(s): FSD

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective Randomized Controlled Trial to Evaluate Fast Track Recovery in Elective Open Infrarenal Aortic Aneurysm Repair
Brief Summary: Fast track programs have been introduced in many surgical fields to minimize postoperative morbidity and mortality. Morbidity after elective open infrarenal aneurysm repair is as high as 30%, mortality ranges up to 10%. In terms of open infrarenal aneurysm repair no randomized controlled trials exist to introduce and evaluate such patient care programs.


Options:
A: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Traditional management | Arm Label: B; Type: EXPERIMENTAL; Interventions: Procedure: Fast track patient management | Intervention Type: PROCEDURE; Name: Fast track patient management; Assigned to Arm(s): B | Intervention Type: PROCEDURE; Name: Traditional management; Assigned to Arm(s): A
B: N/A
C: Arm Label: NMES; Type: EXPERIMENTAL; Interventions: Device: Neuromuscular Electrostimulation (NMES) CareStim Muscle Stimulation Device (Care Rehab; McLean, VA) | Arm Label: Sham; Type: SHAM_COMPARATOR; Interventions: Device: Sham | Intervention Type: DEVICE; Name: Neuromuscular Electrostimulation (NMES) CareStim Muscle Stimulation Device (Care Rehab; McLean, VA); Assigned to Arm(s): NMES | Intervention Type: DEVICE; Name: Sham; Assigned to Arm(s): Sham
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Resistance training | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Usual care | Intervention Type: OTHER; Name: Resistance training; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Oral High-Dose Atorvastatin Treatment in Relapsing-Remitting Multiple Sclerosis
Brief Summary: A phase II open-label baseline-to-treatment trial was designed to evaluate the safety, tolerability and efficacy of orally administered atorvastatin in patients with relapsing-remitting multiple sclerosis (RRMS). Patients with at least one gadolinium-enhancing lesion (CEL) at screening by magnetic resonance imaging (MRI) were eligible for the study. Patients are screened and enrolled in the outpatient clinic of the Cecilie Vogt Clinic at the Charité - University Medicine Berlin. After a baseline period of 3 monthly MRI scans (months -2 to 0), patients followed a 9-month treatment period on 80 mg atorvastatin daily. The primary endpoint is the number of CEL in treatment months 6 to 9 compared to baseline. Secondary endpoints include other MRI-based parameters and changes in clinical scores and immune responses.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: simvastatin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: simvastatin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Interferon-beta-1a, Drug: Simvastatin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Interferon-beta-1a, Drug: Placebo | Intervention Type: DRUG; Name: Interferon-beta-1a; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Simvastatin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
C: Intervention Type: BIOLOGICAL; Name: BHT-3009-01; Assigned to Arm(s): N/A
D: Arm Label: interferon; Type: ACTIVE_COMPARATOR; Interventions: Drug: interferon beta treatment to add-on atorvastatin treatment | Arm Label: untreated; Type: SHAM_COMPARATOR; Interventions: Drug: untreated to atorvastatin treatment | Intervention Type: DRUG; Name: interferon beta treatment to add-on atorvastatin treatment; Assigned to Arm(s): interferon | Intervention Type: DRUG; Name: untreated to atorvastatin treatment; Assigned to Arm(s): untreated

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of Choline Fenofibrate (ABT-335) on Carotid Intima-Media Thickness (cIMT) in Subjects With Type IIb Dyslipidemia With Residual Risk in Addition to Atorvastatin Therapy (FIRST) Trial
Brief Summary: The primary purpose of this study is to test the effect and safety of once daily ABT-335 on the thickness of the lining of the carotid artery (a blood vessel to the brain) in patients with abnormal blood lipids who have optimal levels of low density lipoprotein cholesterol ("bad cholesterol") after taking atorvastatin.


Options:
A: Intervention Type: DRUG; Name: Pactimibe sulfate; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: torcetrapib/atorvastatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: atorvastatin; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: atorvastatin; Assigned to Arm(s): N/A
D: Arm Label: ABT-335 + Atorvastatin; Type: EXPERIMENTAL; Interventions: Drug: ABT-335, Other: Atorvastatin | Arm Label: Placebo + Atorvastatin; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Other: Atorvastatin | Intervention Type: DRUG; Name: ABT-335; Assigned to Arm(s): ABT-335 + Atorvastatin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + Atorvastatin | Intervention Type: OTHER; Name: Atorvastatin; Assigned to Arm(s): ABT-335 + Atorvastatin, Placebo + Atorvastatin

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-center, Randomized, Double-blind, Active-controlled Clinical Trial to Evaluate the Safety and Tolerability of 24 Weeks Treatment With Vildagliptin (50 mg qd) Versus Sitagliptin (25 mg qd) in Patients With Type 2 Diabetes and Severe Renal Insufficiency
Brief Summary: This clinical trial is designed to provide additional information on the safety and tolerability of vildagliptin (50 mg once daily (qd)) and sitagliptin (25 mg qd) when used in patients with type 2 diabetes mellitus(T2DM) and severe renal insufficiency (Glomerular filtration rate (GFR) \< 30 mL/min) for a period of 24 weeks.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Saxagliptin, Drug: Metformin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Metformin | Intervention Type: DRUG; Name: Saxagliptin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): 1, 2
B: Arm Label: Vildagliptin; Type: EXPERIMENTAL; Interventions: Drug: vildagliptin | Arm Label: Sitagliptin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sitagliptin | Intervention Type: DRUG; Name: vildagliptin; Assigned to Arm(s): Vildagliptin | Intervention Type: DRUG; Name: Sitagliptin; Assigned to Arm(s): Sitagliptin
C: Arm Label: BI 1356; Type: ACTIVE_COMPARATOR; Interventions: Drug: BI 1356 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: BI 1356; Assigned to Arm(s): BI 1356 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Rosiglitazone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rosiglitazone | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Rosiglitazone; Assigned to Arm(s): Rosiglitazone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Remote Orthopedic Outpatient Consultation by Help of Telemedicine
Brief Summary: Patients from 4 local communities in northern Norway referred (either new or follow up) to orthopaedic department, University hospital of Northern Norway for outpatient consultation, are randomly assigned to either remote consultation by use of telemedicine (camera and screen), or standard consultation at the hospital. There are x-ray facilities also at the remote site. The patients randomized to telemedicine consultation meet special trained nurses at the remote site, but doctor only by video conference. The patients will be followed for up to one year. The primary endpoint is quality of care achieved with the telemedicine consultation as compared to standard outpatient consultation (assessed by questionnaires filled out by the doctor involved). Secondary end points are patient satisfaction assessed by questionnaires and economic analyses. The study hypothesis is non-inferiority of telemedicine consultation vs. conventional, outpatient consultation.


Options:
A: Arm Label: DIABEO software alone; Type: EXPERIMENTAL; Interventions: Device: DIABEO software | Arm Label: DIABEO+paramedical telemonitoring; Type: EXPERIMENTAL; Interventions: Device: DIABEO software | Arm Label: Usual Follow up; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: DIABEO software; Assigned to Arm(s): DIABEO software alone, DIABEO+paramedical telemonitoring
B: Arm Label: Telemedicine; Type: EXPERIMENTAL; Interventions: Procedure: Ophthalmic Telemedicine | Arm Label: Traditional Surveillance; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Ophthalmic Telemedicine; Assigned to Arm(s): Telemedicine
C: Arm Label: Conventional EMS physician; Type: ACTIVE_COMPARATOR; Interventions: Other: conventional EMS physician | Arm Label: Tele-EMS physician; Type: OTHER; Interventions: Other: tele-EMS physician | Intervention Type: OTHER; Name: conventional EMS physician; Assigned to Arm(s): Conventional EMS physician | Intervention Type: OTHER; Name: tele-EMS physician; Assigned to Arm(s): Tele-EMS physician
D: Arm Label: Standard consultation; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard care in orthopaedic outpatient clinic | Arm Label: Telemedicine consultation; Type: EXPERIMENTAL; Interventions: Other: Telemedicine consultation | Intervention Type: OTHER; Name: Telemedicine consultation; Assigned to Arm(s): Telemedicine consultation | Intervention Type: OTHER; Name: Standard care in orthopaedic outpatient clinic; Assigned to Arm(s): Standard consultation

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Trial to Evaluate the Safety and Immunogenicity of an Investigational Vaccination Regimen in Adults Aged ≥18 Years
Brief Summary: The purpose of this Phase 3, observer-blind, placebo-controlled, multi-center study is to characterize the immunogenicity \& safety of the investigation vaccination regimen of GSK 1557484A vaccine given to adults aged ≥18 years.


Options:
A: Arm Label: Influenza A (H5N1) 18-64Y Group; Type: EXPERIMENTAL; Interventions: Biological: Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted | Arm Label: Placebo 18-64Y Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Arm Label: Influenza A (H5N1) >64Y Group; Type: EXPERIMENTAL; Interventions: Biological: Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted | Arm Label: Placebo >64Y Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Arm Label: Influenza A (H5N1) Group; Type: EXPERIMENTAL; Interventions: Biological: Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Arm Label: Influenza A (H5N1) 18-60Y Group; Type: EXPERIMENTAL; Interventions: Biological: Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted | Arm Label: Placebo 18-60Y Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Arm Label: Influenza A (H5N1) >60Y Group; Type: EXPERIMENTAL; Interventions: Biological: Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted | Arm Label: Placebo >60Y Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted; Assigned to Arm(s): Influenza A (H5N1) 18-60Y Group, Influenza A (H5N1) 18-64Y Group, Influenza A (H5N1) >60Y Group, Influenza A (H5N1) >64Y Group, Influenza A (H5N1) Group | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo 18-60Y Group, Placebo 18-64Y Group, Placebo >60Y Group, Placebo >64Y Group, Placebo Group
B: Intervention Type: DRUG; Name: Influenza vaccination; Assigned to Arm(s): N/A
C: Intervention Type: BIOLOGICAL; Name: Influenza vaccine; Assigned to Arm(s): N/A
D: Arm Label: MI plus respiratory illness; Type: N/A; Interventions: N/A

Answer: A